Multiple System Atrophy (MSA)
Conditions
Interventions
Observation group:none
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Citizens of the People's Republic of China, of any gender, aged between 40 and 85 years; 2. At the initial visit, clinically diagnosed with MSA; meeting the International Parkinson and Movement Disorder Society (MDS) diagnostic criteria for multiple system atrophy (2022 version, see attachment) and the Chinese expert consensus on the diagnosis of multiple system atrophy (2023), independently diagnosed as "clinically probable MSA" by two movement disorder specialists from the Department of Neurology at Huashan Hospital. For patients with disputed diagnoses, the Movement Disorder Specialist Team at Huashan Hospital will collectively discuss and decide. However, necessary auxiliary examinations recommended by the diagnostic criteria must be performed in subsequent research procedures to confirm or revise the diagnosis; 3. Disease symptoms and severity Subjects recruited for this study need to have the basic diagnostic features of MSA. The specific symptom spectrum refers to the diagnostic criteria regarding autonomic failure, Parkinsonian syndrome, and other symptoms. At the initial visit, patients must be able to walk independently without assistance (HY stage less than 4); 4. Fully understand this study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Obvious psychiatric symptoms or severe depressive state; 2. Patients with significant cognitive impairment (MMSE < 20); 3. Severe loss of postural reflexes (unable to stand or walk independently); 4. Dependent on nasogastric tube feeding; 5. Women of childbearing age who are pregnant at the time of enrollment; 6. History of definite brain disease (clear history of stroke, traumatic brain injury, brain tumor, or hydrocephalus); 7. Patients with severe internal diseases of the heart, liver, kidney, etc.; 8. Other conditions considered by the investigator as unsuitable for participation in this study; 9. Concurrent participation in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Unified Multiple System Atrophy Rating Scale(UMSARS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Movement Disorder Society-sponsored Unified Parkinson’s Disease Rating Scale;Simple Mental State Examination (MMSE);The Beck Depression Inventory;Average standardized uptake value of brain regions (SUVmean); | — |
Countries
China
Contacts
Public ContactJian Wang
Huashan Hospital, Fudan University
Outcome results
None listed